AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3mKsQoo
via IFTTT